Form 4: CytomX Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CytomX Therapeutics CEO Sean A. McCarthy sold 37,656 shares of common stock on March 18, 2025, to satisfy tax obligations related to vesting restricted stock units.
Summary
- On March 18, 2025, Sean A. McCarthy, CEO of CytomX Therapeutics, sold 37,656 shares of common stock at a price of $0.599 per share.
- The sale was executed to cover tax or government withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the transaction, McCarthy directly owns 995,195 shares, which includes 488,750 RSUs.
- McCarthy also indirectly owns 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency of trading by corporate insiders.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date of stock sale transaction |
| 03/20/2025 | Date of signature on the Form 4 filing |
Keywords
CytomX Therapeutics, Sean A. McCarthy, stock sale, Form 4, CTMX, restricted stock units, RSUs, tax obligations, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.